Literature DB >> 22707551

Rendu-Osler disease: treatment with oestrogen/progestagen versus octreotide.

Séverin Jeanneret1, Loic Regazzoni, Bernard Favrat.   

Abstract

In Rendu-Osler disease, haemorrhages due to gastrointestinal vascular malformations are common. Surgical and endoscopic treatments for haemorrhage due to gastrointestinal vascular malformations are compromised when lesions are diffuse, escape identification or are inaccessible to treatment. Hormonal treatment with oestrogen and progestagens is still controversial based on contradictory results from two randomised clinical trials. Although somatostatin and its long-acting analogue, octreotide, have been reported to be beneficial in preventing rebleeding, there is no consensus on this type of treatment. This case report shows how the combination of ethinyloestradiol and norethisterone markedly reduced the need for blood transfusions with few side effects in one patient; in comparison, octreotide seems less effective but this could be related to a worsening of the disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22707551      PMCID: PMC3062877          DOI: 10.1136/bcr.11.2010.3534

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  25 in total

1.  Pericarditis complicating esophageal sclerotherapy.

Authors:  P Lewis; D Johnstone; L R Celestin
Journal:  Gastroenterology       Date:  1989-06       Impact factor: 22.682

2.  Estrogen-progestogen therapy for gastrointestinal bleeding in hereditary hemorrhagic telangiectasia.

Authors:  R R McGee
Journal:  South Med J       Date:  1979-11       Impact factor: 0.954

3.  Estrogen-progesterone treatment of Osler-Weber-Rendu disease.

Authors:  E Van Cutsem; P Rutgeerts; K Geboes; F Van Gompel; G Vantrappen
Journal:  J Clin Gastroenterol       Date:  1988-12       Impact factor: 3.062

4.  Hereditary hemorrhagic telangiectasia and danazol.

Authors:  A U Haq; J Glass; C V Netchvolodoff; L M Bowen
Journal:  Ann Intern Med       Date:  1988-07-15       Impact factor: 25.391

5.  Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients.

Authors:  A D Kjeldsen; P Vase; A Green
Journal:  J Intern Med       Date:  1999-01       Impact factor: 8.989

Review 6.  Hereditary hemorrhagic telangiectasia.

Authors:  A E Guttmacher; D A Marchuk; R I White
Journal:  N Engl J Med       Date:  1995-10-05       Impact factor: 91.245

7.  Long-term efficacy of octreotide in the prevention of recurrent bleeding from gastrointestinal angiodysplasia.

Authors:  Félix Junquera; Esteban Saperas; Sebastián Videla; Faust Feu; Jaime Vilaseca; José Ramón Armengol; Josep María Bordas; Josep María Piqué; Juan-Ramón Malagelada
Journal:  Am J Gastroenterol       Date:  2007-02       Impact factor: 10.864

8.  Estrogen-progesterone therapy for bleeding gastrointestinal telangiectasias in chronic renal failure. An uncontrolled trial.

Authors:  M H Bronner; M B Pate; J T Cunningham; W H Marsh
Journal:  Ann Intern Med       Date:  1986-09       Impact factor: 25.391

9.  Estrogen-progesterone therapy for recurrent gastrointestinal bleeding secondary to gastrointestinal angiodysplasia.

Authors:  R Granieri; J P Mazzulla; G W Yarborough
Journal:  Am J Gastroenterol       Date:  1988-05       Impact factor: 10.864

10.  Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone.

Authors:  E van Cutsem; P Rutgeerts; G Vantrappen
Journal:  Lancet       Date:  1990-04-21       Impact factor: 79.321

View more
  1 in total

Review 1.  Role of octreotide in small bowel bleeding.

Authors:  Anwar Khedr; Esraa Elaraby Mahmoud; Noura Attallah; Mikael Mir; Sydney Boike; Ibtisam Rauf; Abbas B Jama; Hisham Mushtaq; Salim Surani; Syed A Khan
Journal:  World J Clin Cases       Date:  2022-09-16       Impact factor: 1.534

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.